<unk> , sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and Drug Administration in February 2015. It was approved for medical use in the European Union in May 2019. The most serious side effect observed is thrombocytopenia (low blood levels of platelets).
Betibeglogene autotemcel
Elivaldogene autotemcel
Literature about intersex
causes of Neoplasm
Human echolocation
Pregnancy specific biological substances
risks of Appendix cancer
MultiPark